Alkermes sank -5.4% this evening, compared to the S&P 500's day change of 1.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Alkermes has logged a 11.0% 52 week change, compared to 8.0% for the S&P 500
-
ALKS has an average analyst rating of buy and is -23.89% away from its mean target price of $36.67 per share
-
Its trailing earnings per share (EPS) is $0.58, which brings its trailing Price to Earnings (P/E) ratio to 48.1. The Health Care sector's average P/E ratio is 24.45
-
The company's forward earnings per share (EPS) is $2.13 and its forward P/E ratio is 13.1
-
The company has a Price to Book (P/B) ratio of 3.63 in contrast to the Health Care sector's average P/B ratio is 4.16
-
The current ratio is currently 2.3, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $59.3 Million and the average free cash flow growth rate is 0.0%
-
Alkermes's revenues have an average growth rate of 0.0% with operating expenses growing at -22.4%. The company's current operating margins stand at -12.8%